Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

9821	Companies
197090	Keywords
128169	Articles
104821	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 07/23/2025 at 14:30, 6 months 15 days ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 6 months 30 days ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 6 months 30 days ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 6 months 30 days ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 8 months 24 days ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 8 months 24 days ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 8 months 24 days ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I
BRIEF

published on 04/09/2025 at 15:20, 9 months 28 days ago

Xenetic Biosciences Shares Promising Preclinical Data at SITC Meeting

Xenetic Biosciences Preclinical Data Solid Tumors DNase Technology CAR-T Cell Therapy
BRIEF

published on 04/09/2025 at 15:20, 9 months 28 days ago

Xenetic Biosciences partage des données précliniques prometteuses lors de la réunion du SITC

Biosciences Xénétiques Thérapie Cellulaire CAR-T Tumeurs Solides Données Précliniques Technologie DNase
PRESS RELEASE

published on 04/09/2025 at 15:15, 9 months 28 days ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette of Xenetic presents positive preclinical data on DNase I intervention enhancing CAR-T cell therapy in solid tumors at SITC 2025 Cell Therapy Meeting. Learn more at Xenetic's website

Immuno-oncology Xenetic DNase I SITC 2025 CAR-T Cell Therapy

Accesswire

Published on 02/07/2026 at 01:00, 17 hours 21 minutes ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 19 hours 11 minutes ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 20 hours 20 minutes ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 2 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 4 hours ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 16:35, 1 hour 46 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 2 hours 1 minute ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 22 hours 56 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 17:40, 1 day ago

Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.26.

Les Echos

Published on 02/06/2026 at 18:22, 23 hours 59 minutes ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 23 hours 59 minutes ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 2 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 2 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 1 day 10 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE